生命科学资讯
生物技术与制药领域的最新动态
Inside the race to thwart the dramatic rise in early-onset colorectal cancer
强生明星药物Spravato为管理迷幻药风险铺路。
J&J’s blockbuster Spravato is setting the stage for managing psychedelics’ risks
中国或将成为大型制药企业的下一个市场新秀。
Big Pharma’s next entrant could come from China
PBM改革如何将制药商推向定价聚光灯下
How PBM reforms could push drugmakers into the pricing spotlight
Biohaven称FDA审批障碍使罕见病患者陷入困境
Biohaven says FDA roadblocks leave rare disease patients in limbo
中国生物医药进步吸引金融投资
China’s biopharma advance draws financial investment
FDA会撤回mRNA疫苗吗？
Will the FDA yank mRNA vaccines?
FDA对迷幻药的真实态度如何？我们或许很快就能知晓。
How does the FDA really feel about psychedelics? We could soon find out.
运营新标准，拯救生命的药品物流
Operating a new standard for life-saving pharmaceutical logistics
默克在肿瘤领域并非单打独斗，其癌症业务版图正持续扩张。
No one-trick pony in oncology, Merck’s cancer footprint is expanding
疫苗监管不确定性会抑制创新吗？制药高管们发声表态。
Will vaccine regulatory uncertainty chill innovation? Pharma execs sound off.
制药业或即将突破血脑屏障。
Pharma could be on the cusp of finally breaking the blood-brain barrier
人工智能正削减各行业岗位，制药业会步后尘吗？
AI is slashing jobs across industries. Will pharma be next?
更多药企转向癌症联合疗法，患者能否因此延长寿命？
More drugmakers are turning to cancer combos. Will it help patients live longer?
赛诺菲为求更“严谨”，以默克前CEO接替赫德森。
Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief
Ovid在新CEO领导下再次在神经科学领域大展拳脚。
Ovid takes another big swing in neuroscience under a new CEO
礼来公司24亿美元押注现货细胞疗法，彰显大型药企战略转型趋势。
Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
专为太空设计的蛋白质模型或将拓展制药业对“可成药性”的定义范畴。
A protein model designed for space could expand pharma’s definition of ‘druggability’
FDA新指南对临床试验意义重大
New FDA guidance that’s a ‘huge deal’ for clinical trials